Loading...
•
Mar 31, 2020
Ardelyx Q1 2020 Earnings Report
Reported financial results for the first quarter ended March 31, 2020.
Key Takeaways
Ardelyx reported $1.2 million in revenue for the quarter ended March 31, 2020. The company's cash, cash equivalents, and short-term investments totaled $223.2 million as of March 31, 2020. Net loss for the quarter was $22.4 million.
Maintained a strong balance sheet with $223.2 million in cash, cash equivalents and short-term investments.
Generated $1.2 million in revenue, primarily from collaborative development.
Preparing NDA submission for Tenapanor for the control of serum phosphorus in mid-2020.
Knight Therapeutics received approval from Health Canada for IBSRELA® for the treatment of IBS-C in adults.
Forward Guidance
Ardelyx is preparing a New Drug Application for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, which the company currently intends to submit to the U.S. Food and Drug Administration in mid-2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...